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Chapter 10
The Use of Non-human Primates
in Research
Kate Chatﬁeld and David Morton
Abstract The use of non-human primates in biomedical research is a contentious
issue that raises serious ethical and practical concerns. In the European Union,
where regulations on their use are very tight, the number of non-human primates
used in research has been in decline over the past decade. However, this decline has
been paralleled by an increase in numbers used elsewhere in the world, with less
regard for some of the ethical issues (e.g. genetic manipulations). There is evidence
that researchers from high-income countries (HICs), where regulations on the use of
non-human primates are strict, may be tempted to conduct some of their experi-
ments in countries where regulation is less strict, through new collaborative efforts.
In collaborative ventures, equivalence in the application of ethical standards in
animal research, regardless of location, is necessary to avoid this exploitation.
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Area of Risk of Exploitation
This case study applies both to academic researchers and to political entities sup-
porting such research. Many areas of research using animals cause public concern,
but none more so than those involving non-human primates. European Union
Directive 2010/63/EU (EU 2010) imposed several stringent conditions on their use
in research, including their acquisition, scientiﬁc reasons for their use, husbandry
and housing conditions, and record keeping, restricting the overall severity of the
procedures carried out, and care of the animals during an experiment. Non-human
primates are used in a number of research ﬁelds, including neurological research
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that involves advanced brain responses which can be tracked in various ways,
safety testing for novel medicines and new batches of vaccines, defence studies and
studies that may beneﬁt wild animals. While in most areas of research the animals
concerned might not suffer extremes of pain, in some they are caused signiﬁcant
mental distress.
Certain types of work envisage substantial human beneﬁts (e.g. defence strate-
gies and antidotes), and this may impel some researchers to seek collaboration
abroad to carry out work that might be limited or severely curtailed in their own
countries. They might also accept compromises in the acquisition of experimental
primates: for instance, wild-caught animals, often seen as local pests, could be used
instead of purpose-bred animals. Furthermore, the application of the “Three Rs” –
replacement, reduction and reﬁnement1 – is likely to be less stringent, particularly
regarding reﬁnement strategies in the housing and husbandry of the animals, and
even more so in the experimental design of studies (e.g. the implementation of
severity limits and humane endpoints).
Animal Research Worldwide
Animal experimentation is used for many biomedical research activities, including
pharmaceutical studies, basic scientiﬁc research, biotechnology and traditional
medicine research. We cannot determine the exact number of animals used
worldwide in research, but there is an estimate of between 50 million and
60 million animal procedures per year, with rats and mice by far the most com-
monly used species (Understanding Animal Research 2015).
It is estimated that non-human primates represent a very small proportion of the
total number of animals used in experiments: fewer than 1 in 1,000 in the EU and
approximately 3 in 1,000 in the US (SCHER 2009). Worldwide, however, the
number may be more than 100,000 each year.
The wide variety of non-human primate species used in research can be divided
into New World species such as marmosets (e.g. the common marmoset, Callithrix
jacchus), and Old World species such as the long-tailed or cynomolgus or
crab-eating macaque (Macaca fascicularis) and the rhesus macaque (Macaca
mulatta). In addition, baboons, another Old World primate of the genus Papio, are
occasionally used.
1The “Three Rs” are the underpinning requirements of most policies and regulations in animal
research:
! Replacement: Methods that avoid or replace the use of animals.
! Reduction: Methods that minimize the number of animals used per experiment.
! Reﬁnement: Methods that minimize suffering and improve welfare.
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Non-human primates are highly valued in biomedical research because of their
genetic similarity to humans,2 which means they can be especially useful for testing
the safety of new drugs and studying infectious diseases, and in neurophysiology,
where they can be trained to respond to external stimuli and their central nervous
system responses monitored or followed in some way.3 However, their similarity to
humans also raises speciﬁc ethical concerns about their use in scientiﬁc experiments
(SCHER 2009).
In the EU, animal experiments are governed by Directive 2010/63/EU (EU
2010) on the protection of animals used for scientiﬁc purposes, which required
member states to apply the provisions of the directive through their national leg-
islation from 1 January 2013. According to the directive, the use of non-human
primates demands special attention and certain requirements have to be met:
Due to their genetic proximity to human beings and to their highly developed social skills,
the use of non-human primates in scientiﬁc procedures raises speciﬁc ethical and practical
problems in terms of meeting their behavioural, environmental and social needs in a lab-
oratory environment. Furthermore, the use of non-human primates is of the greatest concern
to the public (EU 2010: art. 17).
Consequently, the use of non-human primates is strictly controlled and the
purposes for which they can be used require rigorous scientiﬁc justiﬁcation:
Therefore the use of non-human primates should be permitted only in those biomedical
areas essential for the beneﬁt of human beings, for which no other alternative replacement
methods are yet available. Their use should be permitted only for basic research, the
preservation of the respective non-human primate species or when the work, including
xenotransplantation, is carried out in relation to potentially life-threatening conditions in
humans or in relation to cases having a substantial impact on a person’s day-to-day
functioning, i.e. debilitating conditions (EU 2010: art. 17).
There are additional requirements on the provision of life histories and severity
monitoring that add further criteria to try to ensure that the science is of the
highest quality and that animal welfare is not avoidably compromised (EU 2010:
art. 30, 39).
With increased scrutiny and regulation, and in response to public opinion, there
has been a marked reduction in the number of non-human primates being used in
research. Figures show that approximately 6,000 were used in scientiﬁc procedures
in the EU in 2011, compared with almost 10,000 in 2008 (SCHEER 2016).
Furthermore, some institutions are no longer using primates, such as the Harvard
Medical School, which closed its afﬁliated primate facility in 2015. Others are
2For example, baboons have a 91% DNA similarity (see also Wong 2014).
3Safety testing of new drugs, substances and devices, especially those intended for human med-
icine and dentistry, accounts for approximately 67% of the non-human primates used in research.
Fundamental biological research accounts for a further 14% and the research and development of
medical and dental products and devices for humans for about 13% (SCHER 2009).
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reviewing their primate use: for instance, the US National Institutes of Health
announced recently that it would review all non-human primate research that it
funds (Cyranoski 2016).
In light of this trend, the European Commission’s Scientiﬁc Committee on
Health, Environmental and Emerging Risks (SCHEER) announced in June 2016
that it was seeking more information to update the EU directive on the use of
non-human primate research. In particular, it is seeking opinion on areas of research
and testing where non-human primates continue to be used, possibilities to replace
their use, and the potential implications for biomedical research, as well as the
question of whether the use of non-human primates should be banned altogether in
the EU (SCHEER 2016). In Europe, researchers say, the climate for such research is
growing colder (Cyranoski 2016).
While the decrease in the number of non-human primates used in the EU may be
welcomed and regarded as a beneﬁcial impact of Directive 2010/63/EU, there is
rising concern that this decrease has coincided with an increase in the use of
non-human primates elsewhere. There is also concern from some in the scientiﬁc
community that the opportunity to gain valuable insights into certain human dis-
eases will be lost.
Hau et al. (2014) describe how, due to political pressure and the introduction of
the new EU directive, biomedical research with non-human primates is increasingly
difﬁcult to carry out in Europe. Consequently, European scientists are seeking
collaboration with non-human primate centres outside of Europe (Hau et al. 2014).
This has also been noted by Cyranoski (2016), who explains that non-human
primate research increasingly faces “a tangle of regulatory hurdles, ﬁnancial con-
straints and bioethical opposition” (Cyranoski 2016:300). As a result, some
researchers have stopped trying to do such work in the West, and he quotes one
neuroscientist as saying that “red tape drove her to China” (Cyranoski 2016).
There is a long tradition of collaboration between European academic institu-
tions and those in the US and Canada, but the network of collaborating institutions
is becoming increasingly globalized (Macy 2011). This is highly positive in many
respects, but if animals are to be used in collaborative research, the attention to
ethical concerns, animal welfare and the quality of the research must be equivalent
among research partners around the globe4 (Bayne et al. 2015). However, regula-
tions, norms, practices and standards in animal research are not currently harmo-
nized, as is clearly illustrated by the following case.
4The EU have already taken steps towards this end. International projects that are supported by EU
funding, such as the Horizon 2020 funding programme, must ensure that all collaborators in the
project comply with EU laws in their project activities.
84 K. Chatﬁeld and D. Morton
Speciﬁc Case and Analysis
In 2013 a report in the British press alleged that an academic from a UK university
was bypassing British law in his research with wild-caught baboons in Nairobi
(Macrae 2013). A professor of movement neuroscience, part of a team investigating
methods to treat conditions affecting the brain such as stroke, spinal cord injury and
motor neurone disease, was accused of exploiting a cheap and plentiful source of
animals in Nairobi.
The accusation followed an undercover investigation by the British Union for
the Abolition of Vivisection (BUAV), which had covertly obtained photos and
video footage of the baboons at the relevant institute in Nairobi. BUAV contended
that the images revealed disturbing welfare standards and that UK researchers
should not accept lower standards when carrying out research at non-UK facilities.
The UK professor was quoted as saying that while animal welfare standards
were not as high in Nairobi as in the UK, they had improved greatly during his time
there, and that the institute was committed to making further improvements. In
addition, he accepted that the experiments would not be permitted in the UK, but
argued that it was better to capture wild baboons, who had lived for four or ﬁve
years in the wild, rather than breed them in captivity. Experiments on wild-caught
animals are not normally permitted in the UK, but he claimed that the reasons
behind the ban on using wild-caught primates in the UK did not apply to his
experiments in Africa.
In a subsequent article in the Kenyan press, the institute in Nairobi denied
reports that the facility was being used to conduct harmful research on baboons,
claiming that the studies were aimed at advancing medical research for the beneﬁt
of Kenya and the world. It added that out of Kenya’s 13 non-human primate
species, only the two most abundant species (baboons and African green monkeys,
another Old World primate) were being used for biomedical research and that, far
from being endangered, baboons were considered pests in the wild and those being
used in the experiments would otherwise have been killed (Kariuki 2014).
This story received signiﬁcant coverage in the British media, with celebrities
adding their voices to the protests (Nelson 2013). A petition was launched by the
students’ union at the UK university to persuade the university to end such
experiments and, following public pressure, the university decided to halt the
baboon experiments in 2014.
There are two immediate concerns that arise from this case: ﬁrst, that the
standards of animal welfare in Kenya may have been lower than the standards
required in the EU, and second, that the baboons had been taken out of the wild.
It is not possible to make judgements about the equivalence of standards of
animal care without all the facts of the case. However, it is perfectly clear that these
experiments would not have been permitted on wild-caught animals in the UK. Of
the 2,466 non-human primates used in experiments in the UK in 2014, none had
been taken from the wild (Home Ofﬁce 2015).
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It would appear that for many researchers concerns about the equivalence of
standards in animal research are fundamental. As Niemi (2011) points out, with an
unprecedented level of scrutiny of research possible via the internet, the negative
consequences of mere allegations of animal mistreatment are greater than any
theoretical advantage to be gained by conducting animal research in a less rigorous
environment. This sentiment is echoed by Ogden (2011), who maintains that
pharmaceutical and biotech companies do not want to be perceived as using out-
sourcing in order to bypass standards of humane care and use. Generally, it is
acknowledged that the pharmaceutical industry has a vested interest in the pro-
motion of high-quality animal care and facilities and high-quality research outputs
(Medina et al. 2015).
However, even for those with the best of intentions, there are challenges for
collaborative animal research that stem from a lack of consensus on what should be
considered best practice across different cultures. In addition, regulations on animal
research and welfare differ from country to country and are subject to change (Landi
2011).
In China, for example, there does not appear to be the same degree of public
opposition to the use of non-human primates in research, and many new non-human
primate research centres are being established. Some advertise themselves as
“primate-research hubs”, encouraging researchers to fly in and out and make use of
their extensive facilities (Cyranoski 2016).
In Africa, non-human primates are used in research in a number of countries
including Kenya, South Africa and Ethiopia. Some Old World primate species and
baboons are considered agricultural pests in many parts of Africa, and legislation
governing their use in research is generally lacking (Hau et al. 2014).
Most African countries lag behind high-income countries (HICs) in regard to the
existence or adequacy of national and/or institutional policies and guidelines on the
use of animals in research. While some African countries have been developing
ethical or legal frameworks aimed at safeguarding the welfare of animals used for
research, in most African countries there is a serious lack of information in the
public domain. Consequently, some researchers from (HICs) may be tempted to
export their research activities to collaborating African institutions where ethical
and legal frameworks on the use of animals may be less stringent (Nyika 2009).
In 2011, Kimwele, Matheka and Ferdowsian published results from their survey
of 39 highly ranked academic and research institutions in Kenya aiming to identify
those that used animals, their sources of animals, and the application of the Three
Rs. At that time, 28 (71.8%) institutions had no designated committee to review or
monitor protocols using animals. Only two of the institutions with an established
animal care and use committee referred to documented guidelines, and neither
documented the composition of their committees (Kimwele et al. 2011).
Across Africa as a whole, the absence of legal and ethical frameworks and
committees to review protocols that involve animals in research means that animal
protection could be severely compromised, as well as the validity of the scientiﬁc
outcome data. In addition, the lack of institutional animal ethics committees
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promotes the outsourcing of animal research to these unregulated institutions
(Nyika 2009).
This situation is compounded by the fact that most Western academic institu-
tions do not have much experience with local animal care and use regulations in
other countries (Macy 2011). Hence, a double ethics review, where the Western
committee also provides an ethics opinion, is not a solution.
Recommendations
• The overarching requirement for avoiding exploitation in animal research is a
global code of conduct for research involving animals. There are moves towards
this outcome, but it is currently far from resolved. In recent years there have
been attempts from different organizations to develop global frameworks. In
2012, the International Council for Laboratory Animal Science and the Council
for International Organizations of Medical Sciences updated their International
Guiding Principles for Biomedical Research Involving Animals (CIOMS and
ICLAS 2012). These principles incorporate the Three Rs and are intended to
serve as a framework of responsibility for all countries, including those with
emerging research programmes.
• In the absence of a global code of conduct, there will inevitably be variations in
standards, regulations, legislation, scientiﬁc integrity, data validity and humane
practices. In light of this concern, researchers from HICs engaging in collabo-
rative research have an obligation to ensure the application of the same stan-
dards that are upheld in their home nations and home institutions.
• For residents of the EU, this entails full compliance with Directive 2010/63/EU
(EU 2010) in a manner that is both transparent and auditable. Partner institu-
tions must therefore also be transparent and auditable in the application of
principles that are equivalent to those speciﬁed in the directive. This must be a
requirement even when local legislation and regulation are different or less
strict.
• In practice this may entail much closer collaboration with partners on the
ground, working together with local representatives to ensure equivalence in all
activities such as animal housing and care, as well as experimental procedures.
• European funders of research involving animal experimentation have a partic-
ular responsibility to ensure that full compliance with Directive 2010/63/EU is a
necessary condition for their support.
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Conclusion
Although non-human primates constitute a small proportion of the animals used in
research worldwide, their use raises particular ethical concerns. In the absence of a
global code of conduct for animal research, animals in countries where regulations
and legislation are less well formulated are at risk of exploitation in research. For
collaborative ventures, it is vital that institutions from HICs apply precisely the
same standards as are required in their home countries and institutions. This may
entail close working relationships with local partners to ensure equivalence in
standards and some investment to achieve that goal.
For non-human primates, the application of equivalent standards may result in a
reduction in the numbers used in collaborative biomedical research, but it will also
result in more rigorous science and improved welfare standards and a better
application of the Three Rs.
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Commons license, unless indicated otherwise in a credit line to the material. If material is not
included in the chapter’s Creative Commons license and your intended use is not permitted by
statutory regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder.
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